Ligand id: 8713

Name: brolucizumab

Compound class Antibody
Approved drug? Yes (FDA (2019))
International Nonproprietary Names
INN number INN
10053 brolucizumab
Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258
Brolucizumab is a single-chain variable fragment (scFv) anti-VEGF antibody targeting vascular endothelial growth factor A (VEGFA). This immunobinder was derived from a humanised anti-VEGFA rabbit monoclonal [2].
Peptide sequence and secondary structural information are available from brolucizumab's IMGT/mAb-DB record.
Peptide sequence alignment analysis of patented peptide sequences using the heavy chain variable region of brolucizumab identifies a 100% match with SEQ ID NO: 164 in patent US8349322 B2 [1].

Following regulatory approval brolucizumab took its place as a wet age-related macular degeneraton therapy alongside aflibercept (Eylea®) and ranibizumab (Lucentis®), which were previously the main drugs used for this indication. However, with patent protection for both of these older dugs due to expire in the next 2-5 years [4], brolucizumab will likely face competition from aflibercept and ranibizumab biosimilars.
Database Links
Specialist databases
IMGT/mAb-DB 536
Other databases
GtoPdb PubChem SID 252827371
Search PubMed clinical trials brolucizumab
Search PubMed titles brolucizumab
Search PubMed titles/abstracts brolucizumab